Collectively, our results indicate that both anti-apoptotic BCL-2 family members and DRP-1 contribute to melanoma’s resistance to cell death (Fig. 8d), and BH3 mimetics and DRP-1 inhibitors are promising treatment strategies to be further explored. The gene discussed is BCL2; the disease is melanoma.